Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Bernie J. O'Brien"'
Publikováno v:
Canadian Journal of Gastroenterology, Vol 14, Iss 5, Pp 379-388 (2000)
BACKGROUND: Recognition of the pivotal role of Helicobacter pylori in the pathogenesis of peptic ulcer disease has revolutionized primary care approaches to dyspepsia. Decision analysis was used to compare the cost effectiveness of empirical ranitidi
Externí odkaz:
https://doaj.org/article/283d5c1d89e649f88a9236995003e844
Publikováno v:
Canadian Journal of Gastroenterology, Vol 12, Iss 1, Pp 83-90 (1998)
OBJECTIVE: To determine the management of patients with new onset dyspepsia by Canadian family physicians.
Externí odkaz:
https://doaj.org/article/33f1fd495e46413ab95ebce3deb673cf
▪ Abstract As many more clinical trials collect economic information within their study design, so health economics analysts are increasingly working with patient-level data on both costs and effects. In this paper, we review recent advances in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97b2cd01bc67142e1dc2dc5c2d1977cf
https://doi.org/10.1146/annurev.publhealth.23.100901.140534
https://doi.org/10.1146/annurev.publhealth.23.100901.140534
Autor:
Linda MacKeigan, Stephen D. Walter, Gordon H. Guyatt, Bernie J. O'Brien, Femida Gwadry-Sridhar, Evelyn Vingilis, J. Malcom Arnold
Publikováno v:
Contemporary Clinical Trials. 29:905-918
In this manuscript we outline the development of a randomized control trial. Introduction Heart failure (HF) is one of the leading causes of hospitalization in North America. While great advances have been made in the treatment of this disease, many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::893f28c8390f68c4b9603130b867f5da
https://doi.org/10.1016/j.cct.2008.07.001
https://doi.org/10.1016/j.cct.2008.07.001
Publikováno v:
The Journal of Bone and Joint Surgery-American Volume. 89:819-828
Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04878c86dbe60781616e5342fc0e6977
https://doi.org/10.2106/00004623-200704000-00018
https://doi.org/10.2106/00004623-200704000-00018
Autor:
Bernie J. O'Brien, John Marshall, Lisa Dolovich, Anne Holbrook, Adrian R. Levy, Paul Grootendorst
Publikováno v:
Health Services Research. 40:1297-1317
Faced with growing drug expenditures, drug insurance plan executives have adopted various cost containment measures. One such policy, reference pricing (RP), limits drug plan reimbursement of interchangeable medicines to a reference price, which is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0154c2ed1aa6e06068de2a53e8493eaf
https://doi.org/10.1111/j.1475-6773.2005.00420.x
https://doi.org/10.1111/j.1475-6773.2005.00420.x
Autor:
Johan L. Severens, Manuela A. Joore, Elisabeth Fenwick, Bernie J. O'Brien, Daniëlle E. M. Brunenberg
Publikováno v:
PharmacoEconomics. 23:1207-1214
Cost-effectiveness acceptability curves (CEACs) are a method used to present uncertainty surrounding incremental cost-effectiveness ratios (ICERs). Construction of the curves relies on the assumption that the willingness to pay (WTP) for health gain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0ea12faecb8a08c6d9b2f5b8ed17fa
https://doi.org/10.2165/00019053-200523120-00005
https://doi.org/10.2165/00019053-200523120-00005
Publikováno v:
PharmacoEconomics. 23:1083-1106
The economic burden of influenza-related illness has been estimated to be 71.3-166 billion US dollars in the US, the majority of which is attributable to indirect costs as a result of lost productivity. There are currently four antiviral drugs availa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9823f632ca9305b7cb055e1eaafe27f
https://doi.org/10.2165/00019053-200523110-00003
https://doi.org/10.2165/00019053-200523110-00003
Publikováno v:
Statistics in Medicine. 24:1965-1982
Clinical trials of cost-effectiveness are often conducted in more than one country. The two most common ways of dealing with the multinational nature of the data are either to calculate a pooled estimate or to stratify results by country. Since the b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f98d3bdc01306c20064de2cb0f19734
https://doi.org/10.1002/sim.2078
https://doi.org/10.1002/sim.2078
Publikováno v:
Health Economics. 13:405-415
Cost-effectiveness acceptability curves (CEACs) have been widely adopted as a method to quantify and graphically represent uncertainty in economic evaluation studies of health-care technologies. However, there remain some common fallacies regarding t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46ecc5eac387906a67dca8964f4e0a
https://doi.org/10.1002/hec.903
https://doi.org/10.1002/hec.903